XML 37 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue      
Revenue $ 185,308 $ 154,344 $ 98,382
Operating expenses      
Cost of revenue 57,909 49,301 22,530
Research and development 141,756 142,343 116,072
Sales and marketing 95,603 95,465 61,358
General and administrative 88,527 74,502 49,536
Amortization of intangible assets 1,699 1,699 1,703
Total operating expenses 385,494 363,310 251,199
Loss from operations (200,186) (208,966) (152,817)
Interest and other income, net 4,056 1,668 6,590
Interest expense (4,238)    
Net loss (200,368) (207,298) (146,227)
Add: Net loss attributable to noncontrolling interest 177 19  
Net loss attributable to Adaptive Biotechnologies Corporation $ (200,191) $ (207,279) $ (146,227)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (1.40) $ (1.48) $ (1.11)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 142,515,917 140,354,915 131,216,468
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (1.40) $ (1.48) $ (1.11)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 142,515,917 140,354,915 131,216,468